Free Trial
NASDAQ:CALT

Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis

Calliditas Therapeutics AB (publ) logo
$40.00 0.00 (0.00%)
As of 07/24/2025

About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)

Key Stats

Today's Range
$40.00
$40.00
50-Day Range
$40.00
$40.00
52-Week Range
$15.25
$43.00
Volume
N/A
Average Volume
10,339 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter.

CALT Stock News Headlines

[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

CALT Stock Analysis - Frequently Asked Questions

Calliditas Therapeutics AB (publ)'s stock was trading at $40.0001 at the beginning of 2025. Since then, CALT stock has increased by 0.0% and is now trading at $40.0001.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. The company earned $52.36 million during the quarter, compared to analysts' expectations of $42.89 million. Calliditas Therapeutics AB (publ) had a negative net margin of 30.18% and a negative trailing twelve-month return on equity of 212.04%.
Read the conference call transcript
.

Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel served as the underwriters for the IPO and Carnegie was co-manager.

Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Calliditas Therapeutics AB (publ) investors own include Advanced Micro Devices (AMD), Celsius (CELH), NIO (NIO), NVIDIA (NVDA), Reata Pharmaceuticals (RETA), Target (TGT) and Athenex (ATNX).

Company Calendar

Last Earnings
8/13/2024
Today
7/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CALT
CIK
1795579
Fax
N/A
Employees
180
Year Founded
2004

Profitability

EPS (Trailing Twelve Months)
($1.85)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.96 million
Net Margins
-30.18%
Pretax Margin
-29.40%
Return on Equity
-212.04%
Return on Assets
-27.96%

Debt

Debt-to-Equity Ratio
9.44
Current Ratio
2.69
Quick Ratio
2.59

Sales & Book Value

Annual Sales
$1.60 billion
Price / Sales
0.74
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.06 per share
Price / Book
37.74

Miscellaneous

Outstanding Shares
29,790,000
Free Float
29,135,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
1.77

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CALT) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners